Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Irina A. Kirpich · UNIVERSITY OF LOUISVILLE · 2021 · $258,336 — Alcoholic liver disease (ALD) is a major and increasing health problem in the US (especially in Kentucky) and worldwide. In spite of the magnitude of this problem, there is no FDA-approved therapy for any stage of ALD. In addition, the mechanisms and regulators of the disease progression and severit…
Aleksandra Elzbieta Sikora · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2021 · $184,702 — ABSTRACT Neisseria gonorrhoeae (Ng) is a human-specific pathogen and the etiological agent of gonorrhea, a sexually transmitted infection with a significant global health burden of ~78 million new cases annually. While often asymptomatic, untreated gonorrhea can lead to pelvic inflammatory disease, …
Subhash C. Chauhan · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · 2021 · $323,315 — The long-term goal of the proposed research proposal is to develop a targeted paclitaxel nanotherapy that can be used for the treatment of pancreatic cancer (PanCa) in combination with Gemcitabine (GEM). Although many conventional and combinational chemotherapies exist to treat PanCa, significant si…
Marco Brotto · UNIVERSITY OF SOUTH FLORIDA · 2021 · $409,826 — Project Summary Diabetes is a leading cause of death in the US and worldwide with deleterious consequences to the musculoskeletal system. Regardless of glycemic control, diabetes in skeletal muscle manifests with altered metabolism leading to progressive skeletal muscle loss, functional decline, fas…
Admire Dube · STELLENBOSCH UNIVERSITY · 2021 · $336,887 — SUMMARY Tuberculosis remains a major global public health threat. Although relatively effective drug regimens are available, treatment failure remains a major roadblock to tuberculosis control. This is in part due to a high incidence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, as wel…
Hong Chen · BOSTON CHILDREN'S HOSPITAL · 2021 · $796,770 — PROJECT SUMMARY/ABSTRACT Atherosclerosis is the leading cause of life-threatening coronary heart disease, ischemic stroke, and peripheral arterial disease in the United States. Notably, dyslipidemia remains a major risk factor despite effective lipid- lowering therapies and prevention programs. This…
CRAIG J. MCCLAIN · UNIVERSITY OF LOUISVILLE · 2021 · $1,436,994 — The University of Louisville Alcohol Research Center (ULARC) was created to serve as a regional/national resource to perform interdisciplinary collaborative research on the role of nutrition as a cofactor in alcohol induced organ injury and as a possible therapeutic intervention to prevent/treat thi…
Clyde Jason Wright · UNIVERSITY OF COLORADO DENVER · 2021 · $490,696 — PROJECT SUMMARY Bronchopulmonary dysplasia (BPD) is the most common morbidity complicating preterm birth and predicts poor pulmonary and neurodevelopmental outcomes. Despite the well-documented association between inflammation and BPD, no safe and effective anti-inflammatory therapies to prevent BP…
FENG C LIN · CLEVELAND CLINIC LERNER COM-CWRU · 2021 · $402,500 — Abstract Autoimmune uveitis, a common cause of blindness, has an unknown etiology and no known cure. We have been studying experimental autoimmune uveitis (EAU) induced in mice deficient in various complement components, inhibitors, or receptors following active immunization with a retinal antigen …
Anthony D Saleh · MIRECULE, INC. · 2021 · $1,000,000 — Abstract: In this phase 2 SBIR application, miRecule proposes to develop a microRNA-based therapeutic mimic of miR- 30-5p (miRecule candidate MC-30) for the treatment of multi-drug resistant (MDR) cancers. Head and Neck Squamous Cell Carcinoma (HNSCC) is the 6th most common form of cancer. Greater t…
Conrrad Makea Rupe Nicholls · PURDUE UNIVERSITY · 2021 · $36,942 — Project Summary/Abstract Flaviviruses (a family of over 90 known viruses, including Zika, dengue and West Nile) are significant human pathogens affecting 3.1 billion people annually, and most of these enveloped viruses do not have any viable vaccines or antivirals capable of combating their spread.…
Efstathios Karathanasis · CASE WESTERN RESERVE UNIVERSITY · 2021 · $591,126 — PROJECT SUMMARY First-line chemotherapy is the standard of care for patients with triple-negative breast cancer (TNBC). While short-term response is achievable, most patients succumb to recurrence due to metastasis. Micrometastasis encompasses a small population of dormant disseminated tumor cells (…
Margaret M. Billingsley · UNIVERSITY OF PENNSYLVANIA · 2021 · $46,036 — PROJECT SUMMARY CAR T cell immunotherapy is FDA approved for the treatment of acute lymphoblastic leukemia (ALL) and large B cell lymphoma and has shown success in inducing durable remission. However, the therapy is also associated with causing severe, life-threatening side effects—including cytokin…
Raul Andino · ALEPH THERAPEUTICS, INC. · 2021 · $300,000 — SUMMARY The Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UC…
SEBASTIAN JOYCE · VETERANS HEALTH ADMINISTRATION · 2021 — The overarching goal of my research program is to understand the molecular mechanisms of immune surveillance mediated by tissue-resident memory T cells that patrol the mucosal barrier of the lungs to control infectious diseases and cancers. My laboratory is best recognized for its c…
Eric Ervin · ELECTRONIC BIOSCIENCES, INC. · 2021 · $399,999 — Project Summary During this project, Electronic BioSicences (EBS) and Professor Meni Wanunu (at Northeastern University) will develop a true single-molecule, direct, long-lived, RNA sequencer. The developed RNA sequencer will be capable of sequencing RNA with high-accuracy (>99%), as well as iterati…
Gary Liu · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2021 · $66,390 — PROJECT SUMMARY/ABSTRACT Vascular injury and disease during diabetes lead to end-organ dysfunction (kidney failure, blindness, amputation) and cardiovascular disease that profoundly reduces patient quality of life and life expectancy. The proposed work seeks to develop new therapeutics to prevent an…
Gary Leonard Madsen · PROTRANSIT NANOTHERAPY, LLC · 2021 · $261,150 — ABSTRACT This project aims to develop a skincare product to prevent ultraviolet (UV)-induced skin cancer with a novel antioxidant delivery system, Pro-NP™, for topical application alone or as an additive to commercial sunblock. Skin cancer is more common than all other cancers combined and affects m…
Fekadu Kassie · UNIVERSITY OF MINNESOTA · 2021 · $352,275 — PROJECT SUMMARY Lung cancer is the leading cause of cancer-related death in the United States. About 90% of lung cancer cases are associated with genetic/epigenetic changes induced by tobacco smoke (TS). Although all types of lung cells could be affected by TS, the effect on stem cells is particular…
MICHAEL B ELOWITZ · CALIFORNIA INSTITUTE OF TECHNOLOGY · 2021 · $538,984 — Cell targeting with synthetic sense-and-respond protease circuits Abstract A fundamental challenge in biomedicine is developing therapeutics that can target specific cell populations. Synthetic protein circuits, based on engineered proteins that interact with one another and with endogenous cellular…